We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteomika and Auguron Partnered up for DNA-Based Protein Chips in Biomarker Discovery
News

Proteomika and Auguron Partnered up for DNA-Based Protein Chips in Biomarker Discovery

Proteomika and Auguron Partnered up for DNA-Based Protein Chips in Biomarker Discovery
News

Proteomika and Auguron Partnered up for DNA-Based Protein Chips in Biomarker Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteomika and Auguron Partnered up for DNA-Based Protein Chips in Biomarker Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteomika has announced an option agreement with Auguron Biosciences, Inc, giving them rights to exclusive access in two autoimmune disease areas to use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA) technology.

NAPPA technology was developed at the Harvard Institute of Proteomics and is protected by several issued and pending patents, licensed exclusively to Auguron Biosciences. The technology enables fresh, functional proteins to be generated on high density microchips from surface printed DNA.

The Agreement allows Proteomika to manufacture and use NAPPA technology at Proteomika´s facilities for Proteomika´s internal purposes and the performance of services to partners.

At any time during the period, Proteomika may exercise the option to negotiate an exclusive license to NAPPA within the field of biomarker discovery pertaining to Inflammatory Bowel Disease and Lupus. Although the financial details were not disclosed, the companies have stated that the fundamental terms of the license are pre-agreed in the option.

“Having searched for quite some time, we realize NAPPA is the best choice in the proteomics horizon” said Laureano Simon, CEO of Proteomika. “For we want to explore the most powerful reservoir of biomarkers -the immune system.”

Auguron was formed in early 2007 to commercialize developments at the Harvard Institute for Proteomics (HIP). “Auguron is very excited about this agreement. It is the first disease-specific commercial venture for NAPPA and this option sets the stage for Proteomika to fully exploit the power of the platform in two very important disease areas” said Jim Richey, Co-Founder and Chief Executive of Auguron.

Proteomika´s CEO also commented: “NAPPA is the perfect complementary technology to Progenika´s expertise in Molecular Diagnostics, since we will be able to discover autoantibodies in a multiplex fashion. Lupus and IBD sufferers need better biomarkers for diagnosis, prognosis and drug response.”

Advertisement